Guthrie Research Foundation Announces New Clinical Trial for Your Patients with Atrial Fibrillation

The Guthrie Research Foundation has announced a new clinical study for patients with Atrial Fibrillation who have undergone Percutaneous Coronary Intervention. The following study is open to enrollment at the Sayre campus: An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention, sponsored by Janssen Scientific Affairs, LLC, in collaboration with Bayer Pharma AG. The principal investigator is Edo Kaluski, MD, and the research coordinators are Donna Tyburczy, RN and Tina Ostravich, RN.

For information or to enroll a patient, call 570-887-6071.